An antibody, pharmaceutical conjugate thereof and use thereof

CN122302064APending Publication Date: 2026-06-30EVOPOINT BIOSCIENCES CO LTD
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202610640633.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-08-01
Filing Date
2022-09-27
Publication Date
2026-06-30

AI Technical Summary

Technical Problem

The lack of effective monoclonal antibody or ADC drugs targeting Claudin18.2 in current technology, especially in patients with HER2-negative gastric cancer, results in a lack of treatment options and a poor survival rate.

Method used

An anti-Claudin18.2 antibody-drug conjugate (ADC) has been developed, which contains specific heavy chain variable regions and light chain variable regions (CDRs) that can efficiently recognize and bind to Claudin18.2. By linking cytotoxic drugs through a linker, targeted therapy on Claudin18.2-positive tumors can be achieved.

Benefits of technology

It significantly prolongs progression-free survival and overall survival in patients with locally advanced or metastatic gastric cancer, providing a wider range of superior treatment options.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

This invention relates to antibodies and antibody-drug conjugates, and more particularly to antibodies targeting Claudin18.2 (CLDN18.2) and antibody-drug conjugates (ADCs), as well as compositions containing said antibodies and ADC molecules and their therapeutic applications.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Monoclonal antibodies against claudin-18 for treatment of cancer

    CN101312989B

  • Camptothecin peptide conjugates

    WO2019195665A1

  • Bioactive substance conjugate, preparation method therefor and use thereof

    WO2022170971A1